Shares of Selecta Biosciences Inc (NASDAQ:SELB) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $8.44 and last traded at $9.72, with a volume of 380600 shares traded. The stock had previously closed at $11.03.

Several equities analysts have recently weighed in on SELB shares. Canaccord Genuity lifted their price objective on Selecta Biosciences from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, October 12th. Zacks Investment Research raised Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th. ValuEngine lowered Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, UBS Group lowered Selecta Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $23.50.

The firm has a market cap of $192.27 and a P/E ratio of -3.14. The company has a current ratio of 9.48, a quick ratio of 9.48 and a debt-to-equity ratio of 0.32.

In related news, insider Werner Cautreels purchased 20,000 shares of Selecta Biosciences stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average cost of $9.31 per share, with a total value of $186,200.00. Following the transaction, the insider now owns 321,203 shares of the company’s stock, valued at approximately $2,990,399.93. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Timothy C. Barabe purchased 5,000 shares of Selecta Biosciences stock in a transaction that occurred on Friday, November 10th. The shares were bought at an average cost of $9.37 per share, for a total transaction of $46,850.00. Following the completion of the transaction, the director now directly owns 4,992 shares in the company, valued at approximately $46,775.04. The disclosure for this purchase can be found here. Insiders bought a total of 90,098 shares of company stock worth $843,933 over the last ninety days. Corporate insiders own 41.90% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in SELB. Perceptive Advisors LLC lifted its position in Selecta Biosciences by 45.8% during the 3rd quarter. Perceptive Advisors LLC now owns 1,162,325 shares of the company’s stock worth $21,212,000 after acquiring an additional 365,000 shares in the last quarter. Vanguard Group Inc. lifted its position in Selecta Biosciences by 175.5% during the 2nd quarter. Vanguard Group Inc. now owns 217,634 shares of the company’s stock worth $4,322,000 after acquiring an additional 138,646 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Selecta Biosciences by 46.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 358,846 shares of the company’s stock worth $7,126,000 after acquiring an additional 114,477 shares in the last quarter. State Street Corp increased its holdings in Selecta Biosciences by 118.5% during the 2nd quarter. State Street Corp now owns 152,430 shares of the company’s stock worth $3,027,000 after purchasing an additional 82,665 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Selecta Biosciences by 206.5% during the 2nd quarter. Northern Trust Corp now owns 120,993 shares of the company’s stock worth $2,403,000 after purchasing an additional 81,516 shares during the last quarter. 54.44% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/selecta-biosciences-selb-reaches-new-52-week-low-at-8-44/1800059.html.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.